Details for Patent: 11,690,854

Which drugs does patent 11,690,854 protect, and when does it expire?

Patent 11,690,854 protects ORILISSA and is included in one NDA.

This patent has forty-two patent family members in fourteen countries.

Summary for Patent: 11,690,854

Title:	Methods of treating heavy menstrual bleeding
Abstract:	The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
Inventor(s):	Juki Wing-Keung Ng, Mohamad Shebley
Assignee:	AbbVie Inc
Application Number:	US17/047,871
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,690,854
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 11,690,854

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	ORILISSA	elagolix sodium	TABLET;ORAL	210450-001	Jul 23, 2018		RX	Yes	No	11,690,854					MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN A PATIENT WITH MODERATE HEPATIC IMPAIRMENT

International Family Members for US Patent 11,690,854

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018317472
Australia	2018317473
Australia	2018419533
Brazil	112020003380
Brazil	112020003388
Brazil	112020021276